McNicoll, Lewis & Vlak Reiterates Ligand Pharmaceuticals Buy, $30 Price Target

McNicoll, Lewis & Vlak reiterated its Ligand Pharmaceuticals LGND Buy rating and $30 price target in a research report published today. In the report, McNicoll, Lewis & Vlak states, "With 8 marketed drugs and more than 50 fully funded programs, we view LGND as a more de-risked biopharmaceutical investment model with an unprecedented number of individual shots on goal." Shares of Ligand Pharmaceuticals were trading at $13.32 at the time of posting, up 0.99% from Friday's market close.